Hostname: page-component-77f85d65b8-v2srd Total loading time: 0 Render date: 2026-04-13T12:03:24.545Z Has data issue: false hasContentIssue false
  • English
  • Français

Platelet-rich plasma therapy: key infection prevention practices and strategies for safety risk reduction – CORRIGENDUM

Published online by Cambridge University Press:  07 April 2026

Rebecca A. Stern Open the ORCID record for Rebecca A. Stern [Opens in a new window] ,
Jennifer Andrews Open the ORCID record for Jennifer Andrews [Opens in a new window] ,
Katherine Bashaw Open the ORCID record for Katherine Bashaw [Opens in a new window]  and
Thomas R. Talbot Open the ORCID record for Thomas R. Talbot [Opens in a new window]
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Corrigendum
Information
Infection Control & Hospital Epidemiology , First View , pp. 1
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

The author wishes to clarify certain lines in the above article.

Lines 50-52 have been corrected to state: “The nuances of managing a blood product are prudent to incorporate into risk evaluation and logistics, though PRP is technically not classified as a blood product per the Association for the Advancement of Blood & Biotherapies (AABB).”

Lines 199-203, the sentence “As a blood product, PRP regulatory oversight falls under the United States Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), though is exempt from the 21 Code of Federal Regulations 1271.15(b) standard as an autologous product that is readministered to the patient during the same procedure” has been replaced with the following statement: “Importantly, PRP is not treated as a blood product per AABB, though we used standards around blood product administration as best practice for PRP preparation and administration.”

The clarifications have been made and the online HTML and PDF versions updated.

References

Stern, RA, Andrews, J, Bashaw, K, Talbot, TR. Platelet-rich plasma therapy: key infection prevention practices and strategies for safety risk reduction. Infection Control & Hospital Epidemiology. 2026;47(1):1–5. doi:10.1017/ice.2025.10316 CrossRefGoogle Scholar